Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00939094 · ClinicalTrials.gov registry record · Phase 2
AZD2066 Neuropathic Pain - Mechanical Hypersensitivity
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT00939094 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 87 participants.
The verdict
NCT00939094, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate if 28 days of treatment with AZD2066 compared to placebo can relieve the pain arising from the nervous system when the patients are touched by something that should not cause pain or have severe pain when they are touched by something that should only cause a little pain.
Interventions
- DRUG Placebo
- DRUG AZD2066
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00939094
The ClinicalTrials.gov registry entry for NCT00939094 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00939094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00939094 about?
NCT00939094 is a clinical study titled "AZD2066 Neuropathic Pain - Mechanical Hypersensitivity". The purpose of this study is to investigate if 28 days of treatment with AZD2066 compared to placebo can relieve the pain arising from the nervous system when the patients are touched by something that should not cause pain or have severe pain when they are touched by something that should only caus...
What is the current status of trial NCT00939094?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2009-08. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00939094?
The interventions under investigation include: Placebo (DRUG), AZD2066 (DRUG).
Who is sponsoring clinical trial NCT00939094?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.